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Background: Human epidermal growth factor receptor-2 (HER2) overexpression and gene amplification are
currently established by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), respectively. This
study investigates whether high-density single nucleotide polymorphism (SNP) arrays can provide additional
diagnostic power to assess HER2 gene status.
Methods: DNA from 65 breast tumor samples previously diagnosed by HER2 IHC and FISH analysis were blinded
and examined for HER2 copy number variation employing SNP array analysis.
Results: SNP array analysis identified 24 (37%) samples with selective amplification or imbalance of the HER2 region
in the q-arm of chromosome 17. In contrast, only 15 (23%) tumors were found to have HER2 amplification by IHC
and FISH analysis. In total, there was a discrepancy in 19 (29%) samples between SNP array and IHC/FISH analysis. In
12 of these cases, the discrepancy towards FISH could be attributed to concomitant amplification or deletion of the
centromeric region, which harbors the FISH reference probe sequence. In 3 tumors, repeated IHC/FISH analysis
revealed that the original IHC/FISH analysis had failed to indicate the correct HER2 expression level. Finally, the SNP
array analysis revealed that more than two thirds of the samples exhibited polyploidy that was unrecognized by
conventional FISH.
Conclusions: Collectively, the data show that determination of HER2 copy number variations by SNP array-based
genomic segmentation analysis is an effective supplement to IHC/FISH HER2 analysis that, by providing additional
diagnostic sensitivity and accuracy, may elect more women for targeted treatment with HER2 inhibitors.
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Breast cancer is the most common type of cancer among
women and approximately 430,000 new cases are diag-
nosed every year in Europe [1]. Breast cancer develop-
ment and progression rely on several molecular
pathways including estrogen receptor and human epi-
dermal growth factor receptor-2 (HER2) receptor signal-
ing, which represent important prognostic indicators
and provide the molecular basis for targeted treatment
by antibodies or small molecule inhibitors.* Correspondence: fcn@rh.dk
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unless otherwise stated.HER2 is located on chromosome 17q12 and the gene
is amplified in approximately 15–25% of breast cancers
[2,3]. The HER/EGFR family of tyrosine kinases activates
several mitogenic signaling pathways, such as the
MAPK, PI3K/Akt, and mTOR pathways [4], and gene
amplification is associated with a more aggressive course
and reduced expression of estrogen and progesterone
receptors [3,5,6]. On the other hand, antibodies or small
molecule inhibitors such as Trastuzumab and Lapatinib
efficiently inhibit the HER2 receptor and have been
shown to improve overall survival and reduce risk of
relapse [7-11]. Consequently, accurate testing of HER2
amplification is of major importance for clinical
decision-making in breast cancer patients.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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normally established by a combination of immunohisto-
chemistry (IHC) and fluorescence in situ hybridization
(FISH). These procedures have been evaluated in a num-
ber of studies [12-19] and this has revealed that up to
20% of HER2 testing results may be inaccurate [20].
Moreover, external quality assurance tests have indicated
that due to the subjective nature of the IHC scoring
system, fixation procedures, and histopathological as-
sessments, only 75% of the participating laboratories
consistently provided reproducible results [21,22]. As a
result, a number of women are prevented from receiving
the most effective treatment, while others are pointlessly
treated with costly medicine with potentially harmful
side effects [23]. As an illustration of the problem, it has
been highlighted that a number of patients treated with
Trastuzumab responded well [24,25] despite the fact that
they tested negative for HER2 amplification [26]. Finally,
HER2 FISH analysis has difficulties in identifying polys-
omy of chromosome 17 [27], which may complicate the
interpretation of HER2 testing results [28].
Thus, alternative methods are warranted to improve
the accuracy of HER2 analysis. Determination of copy
number variations (CNVs) by high-density single nucleo-
tide polymorphism (SNP) arrays is an appealing possibil-
ity because the technology provides an unbiased and
highly reproducible measure of gene copy numbers.
Furthermore, the analysis provides information about
the entire genome, making it feasible to obtain data from
other genes of interest, such as TOP2A, as they become
validated for breast cancer diagnosis. In the present
study, we assessed the HER2 status of 65 breast tumors
by high-density SNP array analysis and compared the
results with those previously determined by IHC and
FISH. Our data show that SNP arrays provide additional
diagnostic sensitivity and accuracy compared to IHC
and FISH analysis that appears to underestimate the
number of cancers with HER2 amplification. Therefore,
SNP arrays could be a valuable supplement for analysis
of HER2 amplification by assigning more women with
breast cancer to targeted treatment.
Methods
Patient samples
Breast cancer samples were routinely processed accord-
ing to national guidelines. The original stainings and
hybridizations were part of the routine clinical workload
of the Department of Pathology, while SNP arrays were
part of the routine analysis repertoire at the Center of
Genomic Medicine. Therefore the scientific ethics com-
mittee of the Capital Region of Denmark determined
that no ethical approval was necessary (H-3-2013-
FSP55). The research was carried out in compliance with
the Helsinki Declaration. Sixty-five breast cancersamples were collected between 2008 and 2009. The
tumor samples were randomly selected comprising the
following five categories: (1) IHC 0; (2) IHC 1+; (3) IHC
2+, not amplified by FISH; (4) IHC 2+, amplified by
FISH; and (5) IHC 3+. The study aimed to contain 50%
HER 2+ tumor samples.Immunohistochemistry (IHC)
Fresh breast tumor tissue was immediately placed in
formalin fixative and paraffin embedded. Six-micrometer
sections were cut from the tissue blocks and mounted
on Super Frost Plus slides (Menzel-Gläser). HER2 status
was assessed using the HercepTest™ kit K5207 (Dako)
and HercepTest™ Autostainer plus link (Dako) following
the manufacturer’s recommendations. Processed immu-
nohistochemical slides were scored according to the
recommendations of the American Society of Clinical
Oncology/College of American Pathologists [20]. Each
case was categorized as 0, 1+, 2+ or 3+ and specimens
scoring 3+ were considered as HER2 positive. Cases
scoring 2+ were regarded as equivocal and were subse-
quently assessed by HER2 FISH analysis. Cases scored as
0 or 1+ were considered as HER2 negative. All original
stainings were part of the routine clinical workload of
the Department of Pathology and the results were ac-
quired from the clinical records and therefore represent
the actual readings of different pathologists. The analysis
is subjected to both internal and external control (UK
NEQAS).Fluorescence in situ hybridization (FISH)
FISH was performed on all cases scoring 2+ on HercepTest™
and for quality control purposes on a proportion of
the divergent cases from the study group. Sections of
2–4-μm thickness were cut from paraffin blocks,
mounted on Super Frost Plus slides and baked for
60 min at 60°C. HER2 status was assessed using the
HER2 FISH pharmDx™ kit K5331 (Dako). The HER2
probes were labeled with Tx-Red and the control probe
mix targeting the centromere on chromosome 17
(CEP17) was labeled with FITC. The level of HER2
gene amplification was determined in the tissue sec-
tions by counting the green and red signals in the nu-
clei of a minimum of 20 invasive carcinoma cells. The
amplification ratio is the ratio of red to green signals
in each section, using a cut-off point of 2. Cases with a
ratio of 2 or more were regarded to have amplification
of the HER2 gene. All original hybridizations were part
of the routine clinical workload of the Department of
Pathology and the results were acquired from the clin-
ical records and therefore represent the actual readings
of different pathologists. The analysis is subjected to
both internal and external control (UK NEQAS).
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standard protocol was modified as follows. Paraffin sec-
tion thickness was increased to 10–12 μm. Labeling
was performed as described above, except TO-PRO3
(Invitrogen) was applied as a nuclear marker. Sections
were examined on a Zeiss LSM 510 Confocal Micro-
scope, using a 100× objective and a multitrack triple
color setting. Consecutive confocal images were taken
with a thickness of 0.39 μm. Three-dimensional models
were generated from the Z-stack sections using the
Zeiss Image browser software. A minimum of two Z-
stacks containing >30 cells were generated per sample.
The results are stated as the observed average of HER2
copies per nucleus.
DNA purification
DNA was purified from snap-frozen breast cancer sam-
ples macrodissected by a pathologist. The samples were
incubated at 55°C overnight in 200 μl TNES buffer
(10 mM Tris–HCl (pH 7.5), 400 mM NaCl, 100 mM
EDTA, 0.6% SDS) and 20 μl Proteinase K (20 mg/ml).
Genomic DNA was isolated using NaCl precipitation,
washed with 70% ethanol, dried and resuspended in
Tris-EDTA buffer. The DNA integrity was examined by
agarose gel analysis and the DNA concentration was de-
termined using the NanoDrop ND-1000 spectrophotom-
eter (NanoDrop Technologies).
SNP array analysis
Forty-seven DNA samples were analyzed using Affyme-
trix SNP 500 K arrays and 18 DNA samples were ana-
lyzed using the SNP 6.0 array according to Affymetrix’s
instructions. CEL files were analyzed with Partek
Genomics Suite 6.5. Data were imported using the
default Partek settings, including adjustments for probe
sequence, background and quantile normalization, and
allele-specific summarizing of probes. Copy number
state and SNP allele ratio were calculated by an unpaired
analysis using a baseline generated from 76 healthy
Danish controls in the case of the SNP 500 K, and 270
samples from the international HapMap project for the
SNP 6.0 arrays. The average value of all copy number
probe intensity calls across the genome was assigned as
copy number state 2. Segmentation analysis was per-
formed on copy number probe intensity calls using
Partek’s genomic segmentation algorithm, which deter-
mines breakpoints in the data rather than calculating a
predefined copy number state. The algorithm determines
a segment using the following criteria: (1) neighboring
regions have statistically different average intensities
(p < 0.001), (2) breakpoints are chosen to give the best
statistical significance (smallest p-value), (3) detected
regions must contain a minimum number of data
points (SNP 500 K = 100, SNP 6.0 = 200), and (4) theminimum magnitude of changes to be detected relative
to the noise estimate for each chromosome is set to
0.3. The detected segments were analyzed in order to
determine their copy number status (normal, deletion
or amplification). The copy number range was set to
0.2 and the p-value threshold to 0.01, so <1.8 = deletion,
1.8 < × < 2.2 = normal, >2.2 = amplification. In order to
verify that our genomic segmentation model parameters
did indeed call actual strand breaks, we conducted a visual
inspection of predicted strand breaks verifying a change in
allele ratio. This showed that the 1.8 < × <2.2 segmenta-
tion model provides a conservative estimate with no false-
positive strand breaks.
To determine the extent of polyploidy in the tumor
samples, the different copy number fragment states in
combination with the allelic balances at all chromo-
somes was examined. A tumor was assigned as polyploid
if the median intensity probes throughout all chromo-
somes were concluded to be 3 copies or more. It was
not always possible to determine the precise number of
the polyploid state, and in these cases only the lowest
possible estimate is indicated.Results
Pathological characteristics of the breast tumor samples
Sixty-five primary breast tumor samples were selected
for the study, comprising 12 tumors scored as IHC 0, 15
as IHC 1+, 32 as IHC 2+, and 6 as IHC 3+ (Table 1,
HER2 IHC). The HER2/CEP17 ratios of all the IHC 2+
tumor samples were examined by FISH analysis (Table 1,
HER2 FISH). Nine of the IHC 2+ tumors had a HER2/
CEP17 ratio of more than 2.0, 18 IHC 2+ tumor samples
had a HER2/CEP17 ratio between 1.5 and 2.0, while the
remaining 5 IHC 2+ tumor samples had a HER2/CEP17
ratio below 1.5. In total, 15 (23%) tumor samples were
found to have HER2 amplification by IHC and FISH
analysis. Other pathological data is shown in Additional
file 1.SNP array copy number analysis
Sixty-five frozen tumors were initially examined by SNP
500 K or SNP 6.0 arrays in a blinded manner. To exam-
ine the reproducibility of the SNP assay, 10 tumor sam-
ples were initially replicated on newly isolated DNA
using SNP 500 K. All the replicated samples exhibited
identical results. Moreover, CNVs detected by the separ-
ate 500 K StyI and NspI arrays were in all cases com-
pletely overlapping, inferring that the technical variation
in the array-based detection of CNVs was negligible.
Copy number variations and breakpoints were
depicted and the compiled results of all chromosomes
from all tumor samples are shown in Additional file 2.
The tumors exhibited a large number of different CNVs
















1 0 n/a 1,98 balance normal
2 0 n/a 2,35 HER2+ amp*
3 0 1,92 1,81 balance normal
4 0 n/a 2,06 balance normal
5 0 n/a 2,04 balance normal
6 0 n/a 1,72 cent+ del
7 0 n/a 1,67 balance del
8 0 n/a 1,83 balance normal
9 0 n/a 1,51 cent+ del
10 0 n/a 2,51 balance amp*
11 0 n/a 1,78 balance del
12 0 n/a 1,85 balance normal
13 1 n/a 1,97 balance normal
14 1 n/a 2,08 balance normal
15 1 0,83 2,33 balance amp*
16 1 0,80 1,70 balance del
17 1 0,80 1,80 cent+ normal
18 1 0,86 2,49 balance amp*
19 1 n/a 2,06 balance normal
20 1 n/a 2,09 balance normal
21 1 n/a 1,96 balance normal
22 1 n/a 1,97 balance normal
23 1 n/a 2,13 balance normal
24 1 n/a 1,90 balance normal
25 1 n/a 1,87 balance normal
26 1 n/a 4,46 balance amp*
27 1 n/a 2,34 balance amp*
28 2 1,41 2,45 balance amp*
29 2 1,54 2,16 balance normal
30 2 3,05* 2,04 balance normal
31 2 2,69* 2,48 balance amp*
32 2 2,42* 1,75 cent+ del
33 2 1,73 1,99 balance normal
34 2 2,65* 1,92 balance normal
35 2 1,50 1,91 balance normal
36 2 1,57 2,00 balance normal
37 2 1,68 1,79 balance del
38 2 1,90 1,84 balance normal
39 2 1,60 2,05 balance normal
40 2 1,58 1,89 balance normal
41 2 2,13* 2,73 balance amp*
Table 1 Comparison of IHC, FISH and SNP data
(Continued)
42 2 1,54 2,04 balance normal
43 2 1,82 1,54 balance del
44 2 1,90 1,77 balance del
45 2 1,66 2,33 balance amp*
46 2 1,48 2,04 balance normal
47 2 1,73 1,98 balance normal
48 2 1,67 2,36 balance amp*
49 2/3 0,93/8,8 11,10 HER2+ amp*
50 2 1,81 2,04 balance normal
51 2 1,58 2,65 HER2+ amp*
52 2 1,60 2,23 balance amp*
53 2 2,27* 8,03 HER2+ amp*
54 2 1,87 2,91 balance amp*
55 2 1,24 2,66 balance amp*
56 2 7,38* 7,01 HER2+ amp*
57 2 1,00 1,88 balance normal
58 2 8,60* 7,98 HER2+ amp*
59 2 3,24* 3,18 HER2+ amp*
60 3*/1 1,65 2,00 balance normal
61 3 4,11* 5,28 HER2+ amp*
62 3 7,00* 4,58 HER2+ amp*
63 3*/2 1,50 2,05 balance normal
64 3* n/a 3,15 HER2+ amp*
65 3* 1,35 3,75 HER2+ amp*
Asterisk indicates HER2 positive results, while bold indicates samples that have been
reanalyzed. Abbreviations: amp amplified CEP17 centromere on chromosome 17, del
deletion, FISH fluorescent in situ hybridization, HER2 human epidermal growth
factor receptor-2, IHC immunohistochemistry, n/a not analysed.
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results [29,30].
According to the genomic segmentation analysis, 24
(37%) tumor samples exhibited selective amplification of
the HER2 region, whereas 9 had HER2 deletion and 32
exhibited normal HER2 status (Table 1, HER2 copy
number status). Four-fold or greater amplification (4.46–
11.10-fold) of HER2 was observed in 7 samples (tumor
sample 26, 49, 53, 56, 58, 61, and 62), whereas 17 sam-
ples (tumor sample 2, 10, 15, 18, 27, 28, 31, 41, 45, 48,
51, 52, 54, 55, 59, 64, and 65) had a more moderate
HER2 amplification (2.23–3.75-fold). The minimal amp-
lified region surrounding HER2 according to the gen-
omic segmentation algorithm covered ~328 kb DNA
(Figure 1), while the largest amplified region consisted of
a complete duplication of chromosome 17 (in two cases).
The minimal region contained 11 genes that – in addition
to HER2 – comprised partial CDK12, NEUROD2,
































Figure 1 Schematic representation of copy number variations across chromosome 17. The percentiles of SNP samples with amplification
or deletion among the breast tumor samples analysed on SNP 500 K are indicated in red and blue, respectively. The positions of HER2 and the
smallest amplicon containing 9 full-length genes (from 37642255 to 37970066 based on Hg19) are indicated.
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In 46 (71%) tumor samples, the HER2 status was
confirmed by SNP array analysis (Table 1). In 19 (29%)
tumor samples, however, there was a discrepancy be-
tween the SNP analysis and IHC/FISH, including 2/12
(16.7%) of the IHC 0 samples, 4/15 (26.7%) of the IHC 1
+ samples, 11/32 (34.4%) of the IHC 2+ samples, and
2/6 (33.3%) of the IHC 3+ samples. Altogether, the 19
samples comprised 14 IHC/FISH-negative and 5 IHC/
FISH-positive HER2 results. According to the SNP array
data, 11 of the IHC/FISH-negative samples (tumor
sample 10, 15, 18, 26, 27, 28, 45, 48, 52, 54, and 55)
exhibited HER2 amplification without any change in the
HER2/CEP17 ratio. Tumor sample 26 is shown in
Figure 2 as an example. One sample (tumor sample 49)
was reanalyzed by IHC/FISH, and this analysis revised
the classification, previously scored as IHC 2+ with a
HER2/CEP17 ratio of 0.93, to IHC 3+ with a HER2/
CEP17 ratio of 8.8 (Table 1). The last 2 IHC/FISH-nega-
tive samples were scored as IHC 0 (tumor sample 2)
and IHC 2+ (tumor sample 51) with a HER2/CEP17
ratio of 1.58. Both tumor samples had a moderate but
visible HER2 amplification when analyzed by SNP array
(Table 1). Among the IHC/FISH-positive HER2 samples,
2 were IHC 3+ cases (tumor sample 60 and 63). These 2
cases were reanalyzed by IHC and FISH, and were sub-
sequently reclassified as IHC 1+ and IHC 2+, respect-
ively, with a HER2/CEP17 ratio of 1.65 and 1.5,
respectively. The 3 other IHC/FISH-positive samples
were all scored as IHC 2+ (tumor sample 30, 32, and
34) with a HER2/CEP17 ratio of 3.05, 2.42, and 2.65,
respectively. In these cases, the SNP array data classified
the tumor samples as normal (tumor sample 30 and 34)
or with HER2 deletion (tumor sample 32).Polyploidy
During the analysis of the SNP array data, it became evi-
dent that the baseline 2 value was incorrectly mapped in
a number of samples because the SNP probes indicated
imbalance despite the fact that copy numbers were cen-
tered around 2. By combining the information of copy
number fragment states and allelic balances, it was pos-
sible to establish that the samples were in fact polyploid
(defined as having more than 2 sets of all chromosomes).
As an example, tumor sample 5 (Figure 3) did not
exhibit any local CNVs in chromosome 17. However, on
chromosome 14, it could be deducted that the assigned
copy number state 2 intensity value corresponded to 4
DNA copies (for detailed information, please refer to the
figure legend). Additional file 3 shows an additional case
of polyploidy in tumor sample 45. In total, 45 (69%) of
the tumor samples were found to have undergone global
duplication of their entire genome (Table 2). The poly-
ploid status was correlated to HER2 copy number
(Table 2, HER2 copy number estimate). To verify the
calling of polyploidy, we modified the HER2 FISH proto-
col and increased the section thickness to 10–12 μm in
order to encompass a whole nucleus. The sections were
examined by confocal microscopy with high magnifica-
tion and Z-stack imaging generated 3D-rendered recon-
structions of the entire nucleus. Nine samples that were
assigned as being polyploid were examined. Since cells
in late S or G2 phase will display double the amount of
HER2 and CEP17 probe signals, these cells were ex-
cluded from the analysis. The number of HER2 gene
copies (red dots) observed per nucleus/tumor cell is
listed in Table 2 (HER2 copy number per nucleus (3D
FISH)). In all nine cases, the analysis confirmed that the
tumor samples were polyploid. Representative images of
Figure 2 Co-amplification of chromosome 17 centromere and HER2. SNP data from tumor sample 26 displaying the copy number and allele
ratios across chromosome 17. This sample has undergone multiple DNA breaks and several regions of the chromosome 17q arm are amplified,
including a region around HER2 (4.46-fold) and a region close to the centromere. The two regions are amplified to the same extent and may
therefore explain the negative IHC HER2/CEP17 even though the HER2 gene is clearly amplified.
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Additional file 3. In both cases, more than 2 copies of
both HER2 and CEP17 were found to exist. Moreover, in
all nine tumor samples, the observed number of copies
of HER2 (red signal) and CEP17 (green signal) was
found to be in accordance with the estimated copy num-
ber based on SNP array calculations alone. This finding
was confirmed using probes recognizing the centromere
of chromosome 7 (CEP7) and chromosome 17 (CEP17),
respectively (data not shown).
Discussion
According to the guidelines of the American Society of
Clinical Oncology (ASCO)/College of American Pathol-
ogists (CAP), HER2 overexpression and gene amplifica-
tion should be established by a combination of IHC and
FISH. Recent reports indicate, however, that about 20%
of HER2 testing results may be incorrect [20]. Moreover,in a group of HER2 IHC 0 tumor samples, it has been
reported that FISH identified positive HER2 amplifica-
tion in 2–8% of the cases, while 5–22% of HER2 IHC 3+
tumor samples were found to lack HER2 amplification
according to FISH (reviewed in [31]). Since the correct
measurement of HER2 copy numbers is essential for
instigation of targeted therapy [32,33], we investigated
whether it is possible to improve the accuracy of the
analysis by employing high-density SNP arrays.
SNP arrays were developed for global analysis of single
nucleotide polymorphisms, but by adding information
about the intensity of particular SNPs, the analysis may
be exploited to identify CNVs with high sensitivity, reso-
lution, and reproducibility [34,35]. Current high-density
SNP arrays detect CNVs in the range of about 5–10 kb.
Considering that the HER2 amplicon covers at least
280 kb DNA [36,37], the resolution of SNP-based CNV
detection is more than sufficient to provide detailed
Figure 3 Detection of polyploidy. (A) SNP and copy number data across chromosome 17 from tumor sample 5. The top panel displays the
copy number probe intensity calls and the calculated copy number segments (in color). The calculated segment (green line) has an intensity
value of just over 2. The lower panel displays the calculated SNP allele ratios and shows that the entire chromosome 17 is in allelic balance. The
vertical red line indicates the position of HER2. (B) SNP and copy number data across chromosome 14 from tumor sample 5. The enlargement of
the red box shows that a segment (green line) is predicted with an intensity value of just under 2. However, a weak allelic imbalance (green
arrows) suggests that the intensity value of just under 2 does not correspond to 2 DNA copies. Moreover, a deletion (~1.6) and an amplification
(~2.2) only result in a modest copy number intensity change. Taken together, the data in (A) and (B) suggest that a segment with an intensity
value of just over 2 and allelic balance must correspond to at least 4 copies of DNA. (C) Representative image of a 3D-rendered model of a
confocal image stack of a section from tumor sample 5 hybridized with HER2 (red) and CEP17 (green) probes. The image extends 6 μm down into
the z-axis, corresponding to ~60–70% of the nucleus diameter.
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are able to detect alterations in samples containing down
to 10% tumor tissue [38].
Several different algorithms based on simple defined
thresholds to complex statistical modeling have been de-
veloped to call CNVs. We employed a genomic segmen-
tation algorithm which defines breakpoints based on
systematic change in intensity along the chromosome,
unlike the Hidden Markov Model which allocates inten-
sities to a predefined copy number state (0, 1, 2, 3……).
In this way, the segmentation algorithm allows the iden-
tification of CNVs that are less than a whole copy num-
ber state. We considered this to be important for clinical
use because factors such as contamination by normaltissue, tumor heterogeneity, and polyploidy in the tumor
may lead to fractional copy number changes.
The discrepancy between SNP arrays and FISH can be
mainly explained by the fact that 12 amplicons included
the centromeric region of chromosome 17 that harbors
the binding site of the CEP17 reference probe. CEP17
may therefore not be the optimal reference probe and
other centromere probes, e.g. on chromosome 2 or 9,
which comprise few rearrangements in breast tumors
are recommended (Additional file 2). In 3 samples, revi-
sion of the IHC/FISH analysis showed that they were in
fact in agreement with the SNP data. Taken together, the
results indicate that SNP arrays increase the sensitivity
and specificity of the HER2 analysis.
Table 2 Summary of polyploidy
Sample
number
Polyploidy HER2 copy number
estimate
HER2 copy number



























27 Yes 4+ 5-7
28 Yes 4+
29 Yes 4+ 4-6
30 Yes 5+
31 Yes 5+ 5-7
32 Yes 3+
33 No normal
34 Yes 5+ 5-7
35 No normal







43 Yes UPD(2) or amp3 2
Table 2 Summary of polyploidy (Continued)
44 Yes 5+





















Abbreviations: FISH fluorescent in situ hybridization, HER2 human epidermal
growth factor receptor-2, UPD uniparental disomy.
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polyploidy, which is generally considered to reflect
genomic instability and may promote cell transform-
ation [39]. Increased HER2 gene copy number caused
by chromosome 17 polysomy has been reported to be
a contributing factor in HER2 overexpression in other-
wise unamplified invasive breast carcinomas [40]. It
was proposed that cases carrying chromosome 17
polysomy should be further evaluated for HER2 pro-
tein overexpression by IHC. Other studies, however,
have failed to demonstrate a correlation between
chromosome 17 polysomy and expression of HER2
protein [28,41,42].
We observed that more than two thirds of the tumors
studied here were polyploidy, including 18 polyploid
samples determined as IHC 0 or IHC 1+. Although our
tumor material was selected to contain a large number
of IHC 2+ tumors, the data are in contrast to recent
studies reporting chromosome 17 polysomy (defined as
3 or more copies of the chromosome 17 centromere)
with a frequency of 0–46% [27,28,41,43-53]. Compara-
tive genomic hybridization (CGH) array studies in par-
ticular have concluded that chromosome 17 polysomy in
breast cancer is rare and only occurs in about 5% of
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for detection of polyploidy/chromosome 17 polysomy
because the data analysis is based on the Hidden Markov
Model which may fail to uncover polyploidy. Further
studies are required to clarify the significance of
chromosome 17 polysomy in breast cancer patients.
Other techniques of HER2 testing besides IHC and
FISH analysis have previously been suggested, including
chromogenic in situ hybridisation (CISH) [54,55], silver
enhanced in situ hybridisation (SISH) [56], Q-RT-PCR
[57] and multiplex ligation-dependent probe amplifica-
tion (MLPA) [58]. Our study shows that SNP array
should be included as a HER2 testing method as well.
Moreover, recent changes in clinical protocols require
examination of deletions and amplification of the
TOP2A gene as well. In the near term future we expect
a rising demand in the examination of several gene alter-
ations from the same tumor. In this regard SNP chip
array will be a time and money saving procedure investi-
gating these genomic alterations, since it includes the
simultaneous examination of all chromosomes. More-
over, SNP arrays can be analyzed within three working
days, so results can be provided to the clinical depart-
ment in the same time frame as IHC/FISH data. One
limitation for the clinical use of SNP arrays is the use of
fresh-frozen tumor tissue, since fresh-frozen tumor sam-
ples are not available for routine diagnostics in many
countries. However protocols for SNP arrays using
formalin-fixed paraffin-embedded tissue have recently
been described [59], suggesting a broader application of
SNP array analysis in a clinical setting in the near future.
Conclusion
In summary, we conclude that copy number analysis by
means of SNP arrays offers a number of advantages and
improvements that may warrant their use in HER2
diagnostics. Most importantly, array-based analysis is
accurate and identifies more breast tumors for targeted
treatment. The analysis is fast and generates highly
reproducible and quantitative data. Moreover, it provides
a global view that allows rapid evaluation of multiple re-
gions of interest. Future studies are needed to evaluate
response of Trastuzumab in patients with HER2 positive
tumors identified by SNP array analysis. This could be
done retrospective or in a randomised control trial.
Additional files
Additional file 1: Table S1. Pathological data of 65 breast tumors. The
breast tumors consisted of ductal carcinomas, lobular carcinomas, mixed
ductal/lobular carcinomas, or mucinous carcinomas. The tumors were
graded according to the following: Grading 3–5 = Grade 1, 6–7 = Grade 2,
8–9 = Grade 3. The mucinous tumors were not graded. ER and PgR were
regarded as negative (0) when staining is less than 10%. One tumor (29)
was of unknown ER and PgR status. Abbreviations: DC, ductal carcinoma;Diam, diameter; ER, estrogen receptor; LC, lobular cancinoma; MC:
mucinous carcinoma; PgR, progesterone receptor.
Additional file 2: Figure S1. Copy number variations observed in the
65 breast tumors showing the frequencies of genomic copy number
gains and losses plotted according to their genomic localization. Blue
lines correspond to allelic losses and red lines depict gains. Data from
SNP 500 K and SNP 6.0 are displayed separately. Sixty percent of the
tumors have amplification of chromosome 1q. A third of the samples
have amplification of chromosome 5p, while about half of the tumors
have loss of chromosome 8p from p.12 and beyond – frequently in
combination with amplification of chromosome 8q, identified in about
60% of the tumors. Almost a third of the tumors show a high copy
number amplification of the end of chromosome 8 from p.11.21 into the
beginning of p.12 and approximately half of the tumors have loss of
chromosome 11q from q.14.1 to the telomere. Finally, amplification of
chromosome 16p is seen in almost half of the tumors and often in
combination with loss of chromosome 16q, while loss of chromosome
17p is seen in about 40% of the tumors.
Additional file 3: Figure S2. Detection of polyploidy. (A) SNP and copy
number data across chromosome 3 from tumor sample 45. The top
panel displays the copy number probe intensity calls and the calculated
copy number segments (in color). The lower panel displays the calculated
SNP allele ratios of chromosome 3. The calculated segments have varying
intensity values. The fragment with the lowest intensity value represents at
least 3 copies because it exhibits allelic imbalance but still displays SNP
heterozygosity (red arrows). Each fragment can be assigned an increasing
copy number intensity, revealing that the predicted ‘copy number 2’
intensity corresponds to between 5 and 6 copies of DNA. (B) Subsequent
examination of chromosome 17 shows that HER2 must be present in at
least 7 copies. This sample also displays amplification of the centromere
region (q-arm side) to the same extent as HER2, explaining why the FISH
HER2/CEP17 ratio is 1.66. The vertical red line indicates the position of the
centromere and HER2. (C) Representative image of a 3D-rendered model of
a confocal image stack of a section from tumor sample 45 hybridized with
HER2 (red) and CEP17 (green) probes. The image extends 6 μm down into
the z-axis, corresponding to ~60–70% of the nucleus diameter.
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